Page last updated: 2024-12-11
revexepride
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
revexepride: 5-HT4 agonist for treatment of gastro-oesophageal reflux disease [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9823762 |
| CHEMBL ID | 3545035 |
| SCHEMBL ID | 505587 |
| MeSH ID | M000608700 |
Synonyms (24)
| Synonym |
|---|
| 8c63r2y02m , |
| revexepride |
| 219984-49-3 |
| ssp-002358 |
| revexepride [inn] |
| unii-8c63r2y02m |
| 7-benzofurancarboxamide, 4-amino-5-chloro-2,3-dihydro-n-(((3s,4s)-3-hydroxy-1-(3-methoxypropyl)-4-piperidinyl)methyl)-2,2-dimethyl- |
| spd-557 |
| (-)-revexepride |
| 4-amino-5-chloro-n-(((3s,4s)-3-hydroxy-1-(3-methoxypropyl)piperidin-4-yl)methyl(-2,2-dimethyl-2,3-dihydro-1-benzofuran-7-carboxamide |
| r149402 , |
| 7-benzofurancarboxamide, 4-amino-5-chloro-2,3-dihydro-n-(((3r,4r)-3-hydroxy-1-(3-methoxypropyl)-4-piperidinyl)methyl)-2,2-dimethyl- |
| r-149402 |
| SCHEMBL505587 |
| DTXSID30176429 |
| CHEMBL3545035 |
| spd557 |
| HY-U00373 |
| CS-7441 |
| 4-amino-5-chloro-n-(((3s,4s)-3-hydroxy-1-(3-methoxypropyl)piperidin-4-yl)methyl)-2,2-dimethyl-2,3-dihydrobenzofuran-7-carboxamide |
| 4-amino-5-chloro-n-[[(3s,4s)-3-hydroxy-1-(3-methoxypropyl)piperidin-4-yl]methyl]-2,2-dimethyl-3h-1-benzofuran-7-carboxamide |
| Q27270174 |
| MS-27512 |
| AKOS040742543 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic parameters were assessed for up to 48 hours after administration of the investigational product." | ( A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults. Corcoran, M; Hoppenbrouwers, M; Hossack, S; Martin, P; Pierce, D; Velinova, M, 2015) | 0.62 |
| " The pharmacokinetic parameters of revexepride were similar without or with omeprazole co-administration." | ( A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults. Corcoran, M; Hoppenbrouwers, M; Hossack, S; Martin, P; Pierce, D; Velinova, M, 2015) | 0.9 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (100.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 0 (0.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||